Migraine Disorders
23 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Broader: Brain Diseases, Nervous System Diseases
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Allay Lamp for migraine disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Blood sampling for microRNA testing for migraine disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bocunebart for migraine disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BR005-036C for migraine disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Elismetrep for migraine disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Eptinezumab for migraine disorders | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Erenumab for migraine disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 22 |
| Erenumab + calcitonin gene-related peptide for migraine disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Erenumab 70 mg + GALCANEZUMAB + ATOGEPANT + EPTINEZUMAB for migraine disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Erenumab matching placebo + ERENUMAB for migraine disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Erenumab-Aooe 140 MG/ML [Aimovig] for migraine disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Galcanezumab for migraine disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Galcanezumab + erenumab + fremanezumab for migraine disorders | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GALCANEZUMAB + Ubrogepant for migraine disorders | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Green light for migraine disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lidocaine for migraine disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Onabotulinumtoxin-A for migraine disorders | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for migraine disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Placebo + Psilocybin for migraine disorders | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| PRT-064040 nasal spray for migraine disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin for migraine disorders | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Transcranial Direct Current Stimulation for migraine disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ubrogepant + ERENUMAB for migraine disorders | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.